Inhibitors of EYA3 Protein in Ewing Sarcoma

Fahad Hassan Shah1, Song Ja Kim1

  • 1Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 32588, Republic of Korea.

Abstract

Insights

Researchers identified Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione as potential inhibitors for Eyes absent homolog 3 (EYA3). These compounds show promise for treating Ewing sarcoma (EWS) by targeting the EWSR1/FLI1 fusion gene

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ewing sarcoma (EWS) is a highly malignant bone tumor driven by the EWSR1/FLI1 gene fusion.
  • The EWSR1/FLI1 fusion protein activates Eyes absent homolog 3 (EYA3), promoting tumor growth and angiogenesis.
  • EYA3 is recognized as a critical therapeutic target for EWS treatment.

Purpose of the Study:

  • To identify potential EYA3 inhibitors using medicinal compounds.
  • To discover novel therapeutic strategies for Ewing sarcoma.

Main Methods:

  • In silico screening of over 2,000 medicinal compounds from the NuBBE database using PyRX software.
  • Evaluation of compound structural information and binding affinity to EYA3 active residues.

Main Results:

  • Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione demonstrated significant binding affinity to EYA3.
  • These compounds exhibited adequate toxicity and induced cytotoxicity in EWS cells.
  • The identified compounds were capable of regulating gene expression influenced by EWSR1/FLI1.

Conclusions:

  • Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione are promising drug candidates for EWS treatment.
  • Further in vitro testing is recommended to validate their therapeutic potential.

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K